Skip to main content
Other
Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: Implication in vaccine development
US Army Research
  • Anuj Sharma, Uniformed Services University of the Health Sciences
  • Paridhi Gupta, Birla Institute of Technology and Science
  • Pamela J. Glass, US Army Medical Research Institute of Infectious Diseases
  • Michael D. Parker, US Army Medical Research Institute of Infectious Diseases
  • Radha K. Maheshwari, Uniformed Services University of the Health Sciences
Date of this Version
1-1-2011
Comments

Published in Vaccine, 29, (2011), 953–959

Abstract

We have previously shown that a hydrophobic alkylating compound, 1,5-iodonaphthyl-azide (INA) can efficiently inactivate the virulent strain of Venezuelan equine encephalitis virus (VEEV), V3000 in vitro. In this study, we have evaluated the safety of INA-inactivated V3000 and V3526 and the protective efficacy of INA-inactivated V3000. INA-inactivated V3000 and V3526 did not cause disease in suckling mice. RNA isolated from the INA-inactivated V3000 and V3526 was also not infectious. Immunization of adult mice with INA-inactivated V3000 induced an anti-VEEV antibody response and protected mice from virulent VEEV challenge. The protective efficacy of INA-inactivated V3000 increased with the use of adjuvants. Results suggest that inactivation of enveloped viruses by INA may occur by two independent mechanisms and the INA-inactivated VEEV elicit a protective antibody response in mice.

Citation Information
Anuj Sharma, Paridhi Gupta, Pamela J. Glass, Michael D. Parker, et al.. "Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: Implication in vaccine development" (2011)
Available at: http://works.bepress.com/anuj_sharma1/8/